Apixaban Market Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Apixaban is a type of
anticoagulant licenced by the Food and Drug Administration (FDA) that is used
to treat venous thromboembolic events (blood clots that develop within a vein).
VTEs can occur without any prior symptoms or warning signals, and they can go
unnoticed and untreated by a healthcare expert. Pain in the calf, swelling in
the ankle or foot, redness or obvious discolouration areas, rapid breathing,
chest pain, and other symptoms may be associated with either deep vein
thrombosis (DVT) or pulmonary embolism (PE). Apixaban is commonly prescribed to
people with nonvalvular atrial fibrillation to lower the risk of stroke and
systemic embolism.
Rising therapeutic indications
for apixaban will drive market growth, as will an increase in the prevalence of
atrial fibrillation, venous thromboembolism, and stroke, an increase in the
number of geriatric population, an increase in the prevalence of obesity, an
increase in healthcare expenditures worldwide, and an increase in government
and private organisations significantly investing capital in healthcare
research and development, among other factors driving the apixaban
market. Furthermore, expanding potential in emerging nations, as well
as increasing technical developments and modernization in the healthcare
sector, will generate new chances for the apixaban market during the projected
period of 2021-2028.
This apixaban market report
discusses market share, new developments, and product pipeline analysis, the
impact of domestic and localised market players, emerging revenue pockets,
changes in market regulations, product approvals, strategic decisions, product
launches, geographic expansions, and technological innovations.
Comments
Post a Comment